GlassScriptPhysician profile
Heidi A Berdin
NPI 1659368751
$13,661.74
in general payments reported to CMS, 2019-2025
32 companies · $2,238 in 2025
The $2,238 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,727 · 2020: $1,570 · 2021: $1,758 · 2022: $1,786 · 2023: $1,734 · 2024: $2,849 · 2025: $2,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,093 · Travel and Lodging: $677 · Education: $50.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,092.94 |
| Travel and Lodging | $676.91 |
| Education | $50.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,712.14 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,904.51 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $919.76 | 2019-2025 | Winrevair, Belsomra |
| Intuitive Surgical, INC. | $847.39 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $835.37 | 2019-2025 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $831.24 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $599.93 | 2020-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $564.01 | 2021-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $554.98 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $286.47 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $258.35 | 2020-2023 | Glassia |
| Biohaven Pharmaceuticals, INC. | $250.00 | 2021 | |
| Insmed, INC. | $247.64 | 2019-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $220.34 | 2019-2025 | Encore, (8874) Incourage |
| Inspire Medical Systems, INC. | $207.81 | 2023 | Inspire |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $182.56 | 2022-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Volara System, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $166.42 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $148.71 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $145.77 | 2019 | |
| Siemens Medical Solutions USA, INC. | $138.49 | 2024 | |
| Genentech USA, INC. | $99.75 | 2019-2021 | |
| Grifols USA, LLC | $83.60 | 2019-2021 | |
| Genzyme Corporation | $78.05 | 2019-2021 | |
| Advanced Respiratory, INC | $65.31 | 2020-2021 | |
| Viatris Specialty LLC | $58.84 | 2025 | Yupelri |
| Lilly USA, LLC | $50.70 | 2025 | Zepbound |
| Gilead Sciences, INC. | $47.79 | 2021 | |
| Shire North American Group INC | $43.30 | 2019 | |
| Itamar Medical INC | $42.06 | 2023 | Watchpatone |
| 3b Medical, INC. | $24.13 | 2025 | Luna |
| Boston Scientific Corporation | $23.56 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Berdin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.